文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

中高危前列腺癌外照射联合高剂量率近距离治疗:外照射体积的影响

External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-11

PURPOSE: Whole pelvis radiation therapy (WPRT) may improve clinical outcomes over prostate-only radiation therapy (PORT) in high-risk prostate cancer patients by sterilization of micrometastatic nodal disease, provided there is optimal control of the primary site.…

要点

  • WPRT增加急性泌尿和胃肠道毒性,但晚期毒性无差异。

核心结论

  • 在中高危前列腺癌患者中,采用外照射联合高剂量率近距离治疗方案时,WPRT较PORT显著改善5年生化无进展生存率,且未增加晚期放疗毒性。

研究设计与样本

  • WPRT剂量为46 Gy分23次,PORT剂量为37.5 Gy分15次,均联合单次15 Gy高剂量率近距离治疗。
  • 主要终点为生化无进展生存率,次要终点为总生存、泌尿生殖毒性和胃肠道毒性。

主要发现

  • 调整Gleason评分、就诊时前列腺特异性抗原、T分期和雄激素剥夺治疗时长后,bPFS差异仍显著。
  • 总生存无差异。

关键数值与推荐

  • 任何随访时间点≥3级毒性不超过1.5%。

临床怎么用

  • 对于接受外照射联合高剂量率近距离治疗的中高危前列腺癌患者,可考虑采用全盆腔放疗以改善生化控制。
  • 需权衡WPRT增加的急性泌尿和胃肠道毒性,但晚期毒性未见增加。

局限性

  • 非随机对照比较,存在偏倚可能, findings为假设生成性,不能作为确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Whole pelvis radiation therapy (WPRT) may improve clinical outcomes over prostate-only radiation therapy (PORT) in high-risk prostate cancer patients by sterilization of micrometastatic nodal disease, provided there is optimal control of the primary site. METHODS AND MATERIALS: A prospective multicenter cohort study of eligible patients (stage ≥T2c, Gleason score ≥7 or presenting prostate-specific antigen ≥10) treated between 2009 and 2013 were enrolled in a United Kingdom national protocol delivering combined external beam radiation therapy and high-dose-rate brachytherapy. Centers elected to deliver WPRT, 46 Gy in 23 fractions or PORT 37.5 Gy in 15 fractions with 15 Gy single dose high-dose-rate brachytherapy. The primary endpoint was biochemical progression-free survival (bPFS). Secondary endpoints were overall survival, genitourinary, and gastrointestinal toxicity. This was not a randomized comparison and was subject to bias; the findings are therefore hypothesis generating, but not conclusive. RESULTS: Eight hundred and twelve patients were entered; 401 received WPRT and 411 received PORT. With a median follow-up of 4.7 years, 5-year bPFS rates for WPRT versus PORT arms were 89% versus 81% (P = .007) for all patients and 84% versus 77% (P = .001) for high-risk patients. Differences in bPFS remained significant after accounting for Gleason score, presenting prostate-specific antigen, T stage, and androgen deprivation therapy duration as covariates. There was no difference in overall survival. The overall post treatment toxicities across both cohorts were low with no greater than 1.5% of ≥grade 3 toxicities at any follow-up time point. WPRT increased both prevalence and cumulative incidence of acute genitourinary toxicity (P = .004) and acute gastrointestinal toxicity (P = .003). No difference in late radiation toxicity was observed. CONCLUSIONS: A significant improvement in 5-year bPFS was seen in intermediate and high-risk prostate cancer treated with WPRT compared with PORT in a combined external beam radiation therapy and brachytherapy schedule with no increase in late radiation toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tharmalingam H, Tsang Y, Choudhury A, et al. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. Int J Radiat Oncol Biol Phys. 2019. PMID: 31610249. doi:10.1016/j.ijrobp.2019.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。